RT Journal Article
SR Electronic
T1 What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e000506
DO 10.1136/lupus-2021-000506
VO 8
IS 1
A1 Johanna Mucke
A1 Marta Alarcon-Riquelme
A1 Jeanette Andersen
A1 Martin Aringer
A1 Stefano Bombardieri
A1 Ralph Brinks
A1 Ricard Cervera
A1 Gamal Chehab
A1 Alain Cornet
A1 Nathalie Costedoat-Chalumeau
A1 László Czirják
A1 Andrea Doria
A1 Rebecca Fischer-Betz
A1 Richard A Furie
A1 Mariele Gatto
A1 Frédéric A Houssiau
A1 Luis Ines
A1 Matthew H Liang
A1 Eric Morand
A1 Marta Mosca
A1 José María Pego-Reigosa
A1 Iñigo Rúa-Figueroa
A1 Guillermo Ruiz-Irastorza
A1 Benjamin Terrier
A1 Anne Voss
A1 Matthias Schneider
YR 2021
UL http://lupus.bmj.com/content/8/1/e000506.abstract
AB Despite promising candidates for new therapeutic options in the treatment of systemic lupus erythematosus (SLE), many clinical trials have failed in the past few years. The disappointing results have been at least partly be attributed to trial designs. With the aim of stimulating new developments in SLE trial design, an international open space meeting was held on occasion of the European Lupus Meeting 2018 in Duesseldorf, Germany about ‘What are the topics you care about for making trials in lupus more effective?’. The Open Space is a participant-driven technology, where the discussion topics and schedule are selected during the meeting by all participants and discussion rounds are led by the people attending encouraging active contributions. Eleven topics were selected for further discussion, of which 6 were voted to be more intensively discussed in two consecutive rounds. Major topics were the optimal handling of glucocorticoids in clinical trials, the improvement of outcome measures, reducing or controlling the placebo response and the identification of biomarkers and stratification parameters. Further, the importance of local and international networks was emphasised. By networking, collaborations are facilitated, patient recruitment is more efficient and treatment can be harmonised thus lead to more successful SLE trials. Further discussions are needed to substantiate the results and develop new trial designs.